Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month
New Outcomes Research in Patients With Schizophrenia or Bipolar I Disorder to be Presented
Published 05-04-21
Submitted by Alkermes
DUBLIN, May 4, 2021 /CSRwire/ Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May. The meetings, all held virtually, include:
American Psychiatric Association (APA) Annual Meeting, May 1-3;
International Society for Bipolar Disorders (ISBD) Annual Conference, May 13-15;
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, May 17-20.
G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -
News provided by
Share this article
Share this article
DUBLIN, April 20, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021.
The company s presentations included new exploratory analyses from the phase 3 ENLIGHTEN-2 study of olanzapine/samidorphan (LYBALVI™), formerly referred to as ALKS 3831, including:
Results from prespecified subgroup analyses evaluating olanzapine/samidorphan s effect on weight gain across several patient subgroups, including those known to be at higher risk for weight gain with olanzapine, based on sex, race, age and ba
Press release content from Business Wire. The AP news staff was not involved in its creation.
Bayer to Present New Clinical Data in Indolent non-Hodgkin’s Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021
April 6, 2021 GMT
WHIPPANY, N.J. (BUSINESS WIRE) Apr 6, 2021
Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021. The data include an oral presentation in a Clinical Trials Plenary Session on the Phase III randomized, double-blind, placebo-controlled clinical study of the investigational use of Aliqopa ® (copanlisib) in combination with rituximab given intravenously in patients with relapsed indolent non-Hodgkin’s Lymphoma (iNHL) who have relapsed after ≥1 line of treatment, including rituximab (CHRONOS-3).
FDA Approves G1 Therapeutics’ COSELA™ (trilaciclib): The First and Only Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
February 12, 2021 19:41 ET | Source: G1 Therapeutics G1 Therapeutics
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with
extensive-stage small cell lung cancer being treated with chemotherapy -
- Myeloprotective efficacy of COSELA resulted in reductions in the incidence and duration of severe neutropenia, and impacted anemia and the need for rescue interventions such as growth factors and red blood cell transfusions -
- G1 will host conference call Tuesday, February 16, 2021 at 8:00 a.m. ET -
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2021 (GLOBE NEWSWIRE) G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved COSELA�